Nature Communications (May 2020)
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
- Neha Chopra,
- Holly Tovey,
- Alex Pearson,
- Ros Cutts,
- Christy Toms,
- Paula Proszek,
- Michael Hubank,
- Mitch Dowsett,
- Andrew Dodson,
- Frances Daley,
- Divya Kriplani,
- Heidi Gevensleben,
- Helen Ruth Davies,
- Andrea Degasperi,
- Rebecca Roylance,
- Stephen Chan,
- Andrew Tutt,
- Anthony Skene,
- Abigail Evans,
- Judith M. Bliss,
- Serena Nik-Zainal,
- Nicholas C. Turner
Affiliations
- Neha Chopra
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research
- Holly Tovey
- Clinical Trials and Statistics Unit, The Institute of Cancer Research
- Alex Pearson
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research
- Ros Cutts
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research
- Christy Toms
- Clinical Trials and Statistics Unit, The Institute of Cancer Research
- Paula Proszek
- The Centre for Molecular Pathology, The Royal Marsden Hospital
- Michael Hubank
- The Centre for Molecular Pathology, The Royal Marsden Hospital
- Mitch Dowsett
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research
- Andrew Dodson
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital
- Frances Daley
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research
- Divya Kriplani
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research
- Heidi Gevensleben
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research
- Helen Ruth Davies
- Department of Medical Genetics, The Clinical School
- Andrea Degasperi
- Department of Medical Genetics, The Clinical School
- Rebecca Roylance
- University College London Hospitals NHS Foundation Trust, NIHR University College London Hospitals Biomedical Research Centre
- Stephen Chan
- Nottingham University Hospital Trust (City Campus)
- Andrew Tutt
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research
- Anthony Skene
- Royal Bournemouth Hospital
- Abigail Evans
- Poole Hospital NHS Foundation Trust
- Judith M. Bliss
- Clinical Trials and Statistics Unit, The Institute of Cancer Research
- Serena Nik-Zainal
- Department of Medical Genetics, The Clinical School
- Nicholas C. Turner
- Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research
- DOI
- https://doi.org/10.1038/s41467-020-16142-7
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 12
Abstract
Defects in homologous recombination (HR) are found in some triple negative breast cancers, suggesting they may be sensitive to PARP inhibitors. In this phase II clinical trial of the PARP inhibitor rucaparib, changes in Ki67 levels did not correlate with markers of HR deficiency but HR deficiency was detected in 69% of tumours, indicating that PARP inhibitors may be a useful treatment.
